Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.42, Iss.5, 2003-01, pp. : 419-436

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dose Dependency of Pharmacokinetics and Therapeutic Efficacy of Pegylated Liposomal Doxorubicin (DOXIL) in Murine Models

By Gabizon Alberto Tzemach Dinah Mak Lidia Bronstein Moshe Horowitz Aviva T.

Journal of Drug Targeting, Vol. 10, Iss. 7, 2002-01 ,pp. : 539-548

Informa Healthcare

Access to resources Recommend Favorite

Pegylated Liposomal Doxorubicin: A Review of its Use in the Treatment of Relapsed or Refractory Multiple Myeloma

By Plosker Greg L.

Drugs, Vol. 68, Iss. 17, 2008-01 ,pp. : 2535-2551

Adis International

Access to resources Recommend Favorite

Pegylated Liposomal Doxorubicin: A Review of its use in Metastatic Breast Cancer, Ovarian Cancer, Multiple Myeloma and AIDS-Related Kaposi's Sarcoma

By Duggan Sean T. Keating Gillian M.

Drugs, Vol. 71, Iss. 18, 2011-12 ,pp. : 2531-2558

Adis International

Access to resources Recommend Favorite

Pegylated liposomal doxorubicin is active and well tolerated in elderly women with metastatic breast cancer

Inpharma, Vol. 1, Iss. 1649, 2008-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas

By Stroppa Elisa Bertuzzi Alexia Comite Gabriele Mussi Chiara Lutman Romano Barbato Alfredo Santoro Armando

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 834-838

Springer Publishing Company

Access to resources Recommend Favorite